Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-resistant tuberculosis: what do we do now?

A Telenti1, M Iseman

  • 1Division of Infectious Diseases and Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. amalio.telenti@chuv.hospvd.ch

Drugs
|March 24, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2016
Same author

Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population.

Open forum infectious diseases·2015
Same author

Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013.

Open forum infectious diseases·2015
Same author

Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study.

Open forum infectious diseases·2015
Same author

Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.

The Journal of antimicrobial chemotherapy·2014
Same author

[An update on hepatitis E].

Revue medicale suisse·2013

Drug-resistant tuberculosis (TB) poses a significant threat to global health. While understanding of resistance mechanisms and directly observed therapy has advanced, new drug development and rapid diagnostics for TB remain limited.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Public Health

Background:

  • Drug-resistant tuberculosis (TB) is a major challenge to global TB control efforts.
  • Factors contributing to this threat include erratic medication use, HIV-TB co-infection, and transmission of resistant strains.
  • The current landscape presents a concerning picture for managing TB.

Purpose of the Study:

  • To review the current understanding of drug-resistant tuberculosis.
  • To assess progress in antituberculosis agent mechanisms and resistance.
  • To evaluate the development of new compounds and diagnostic tests for global TB control.

Main Methods:

  • Literature review of recent advancements in tuberculosis research.
  • Analysis of mechanisms of action and resistance to antituberculosis agents.

Related Experiment Videos

  • Evaluation of the impact of directly observed therapy (DOT).

    • Main Results:

    • Significant progress has been made in understanding resistance mechanisms and the efficacy of directly observed therapy (DOT) in preventing treatment failure.
    • However, development of novel antituberculosis compounds and rapid diagnostic tests has been limited.
    • The relevance of these limited developments to global TB control has been questioned.

    Conclusions:

    • Despite advancements in understanding drug resistance and treatment strategies like DOT, a critical gap exists in the development of new drugs and rapid diagnostics for tuberculosis.
    • Addressing this gap is crucial for effective global TB control programs.
    • Further research and investment are needed to combat the growing threat of drug-resistant TB.